News
Volition RX (re)searches... and proves it to the Ambassador of the United States
VolitionRx Limited, a multinational epigenetics company established at Créalys®, welcomed Michael M. Adler, United States ambassador to the Kingdom of Belgium, for a visit to the research, development and manufacturing facilities of this jewel of Walloon R&D.
As Volition is present on both sides of the Atlantic, Ambassador Adler’s visit was a great opportunity to celebrate the collaboration and stress the close links which the company has forged between the American and Belgian stakeholders over the past 13 years.
R&D and manufacturing in Belgium, a state-of-the-art lab in California
Volition develops simple blood tests, which are easy to use and cost effective, to help diagnose and monitor various potentially life-changing diseases, in particular certain cancers and diseases associated with NETosis, such as sepsis and Covid-19.
With specially designed R&D and manufacturing facilities in Belgium and a state-of-the-art innovation laboratory in California, Volition operates on both sides of the Atlantic.
“As a company, we benefit enormously from this pool of talent, the joint collaboration and the shared experience, which have definitely helped us grow faster. Our subsidiary, Volition Veterinary Diagnostics Development LLC, was born of collaboration with Texas A&M University and has allowed us to launch the Nu.Q® Vet cancer text commercially in the United States. Cultivating successful, lasting relations with stakeholders across the world was vital for the development of Volition.”Gaëtan Michel, Director of Operations at Volition
Volition’s current product portfolio includes the Nu.Q® Vet cancer test, a diagnostic tool for the early detection and monitoring of cancer in dogs, and Nu.Q® NETs, a test with CE marking to detect diseases associated with NETosis.
The group holds 95 patents with a further 126 under investigation and is listed on the New York Stock Exchange (NYSE American).
About Volition technologies
Volition is a multinational epigenetics company fuelled by Nu.Q®, its proprietary platform for the quantification of nucleosomes. Through its subsidiaries, Volition develops simple blood tests that are easy to use and cost-effective, for the preventive detection of sometimes serious illnesses. Early diagnosis and monitoring have the potential not only to prolong patients’ lives but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which involves identifying and measuring the nucleosomes in the blood or other bodily fluids – an indication of the presence of the disease.
Volition’s research and development activities are centred in Belgium, at the Créalys® business park in Namur, with an innovation laboratory and most of the team, as well as an office in the United States and additional offices in London and Singapore.
The company’s workforce currently comprises 60 employees in Belgium and 26 in the USA, at its subsidiary established in 2017, among others.
US Ambassador Adler visits Belgian Volition
And the BEP in all this?
Gaëtan Michel, Director of Operations at Volition, declared during the visit: “We were delighted to welcome Ambassador Adler to Volition today to present our team of experts, highlight our revolutionary epigenetic technology and stress its potential for improving patients’ results all over the world.”
But he also pointed out once again that it is thanks to the BEP that he was easily able to identify the first building that the company had been able to acquire in 2016, in order to relocate there after leaving the UNamur laboratories, and establish huge laboratories, but also in 2020 to expand into a second building acquired in the same street, which was essential to create a real production unit.
Are you, too, considering the idea of finding new Life Sciences development spaces in the Province of Namur?
Find out more about healthcare and the silver economy in the Province of Namur